Zogenix, Inc. (NASDAQ:ZGNX) is anticipated to reveal earnings on May, 8., as reported by RTT. Last year’s earnings per share was $-0.87, while now analysts expect change of 10.34 % down from current $-0.96 earnings per share. Analysts at Wall Street see Zogenix, Inc.’s 81.13 % negative EPS growth compared to $-0.53 earnings per share for last quarter. ZGNX is hitting $52 during the last trading session, after increased 0.95%.Zogenix, Inc. has 938,211 shares volume, 100.14% up from normal. ZGNX is uptrending and has moved 24.68% since April 6, 2018. The stock outperformed the S&P500 by 20.31%.

Zogenix, Inc. (NASDAQ:ZGNX) Ratings Coverage

A total of 4 analysts rate Zogenix (NASDAQ:ZGNX) as follows: 4 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:ZGNX) has 9 ratings reports on Apr 6, 2019 according to StockzIntelligence. On Friday, March 1 the rating was maintained by Mizuho with “Buy”. On Tuesday, March 19 the rating was maintained by Mizuho with “Buy”. On Tuesday, March 12 the stock of Zogenix, Inc. (NASDAQ:ZGNX) has “Buy” rating given by Mizuho. On Tuesday, March 19 the firm has “Buy” rating given by Northland Capital.

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States.The company has $2.21 billion market cap. The company's lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.Last it reported negative earnings. It also develops Relday, an injectable formulation of risperidone to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older.

For more Zogenix, Inc. (NASDAQ:ZGNX) news announced briefly go to: Nasdaq.com, Nasdaq.com, Seekingalpha.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results – Nasdaq” announced on February 28, 2019, “Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) – Nasdaq” on April 01, 2019, “Zogenix files marketing applications for Fintepla for Dravet – Seeking Alpha” with a publish date: February 06, 2019, “Why Zogenix Shares Soared 20.5% in February – Nasdaq” and the last “Zogenix to Present at Two Investor Conferences in April – Nasdaq” with publication date: March 25, 2019.